Allspring中小型核心主動型ETF ASCE 深 滬
等待開盤 05-20 09:30:00 美东时间
30.976
-0.307
-0.98%
華盛通- 最 高31.21
- 今 開30.90
- 成交量 1.03万股
- 最 低 30.81
- 昨 收 31.2831
- 總市值 7025.36万
- 52周最高 32.97
- 市盈率 靜 --
- 換手率 0.46%
- 52周最低 24.0619
- 委 比 0.00%
- 總股本 226.80万
- 歷史最高 32.97
- 量 比 0.42
- 振 幅 1.28%
- 歷史最低 24.0619
- 每 手 1
- 風險率 1.94%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多HLS Therapeutics Q1 2026 Earnings Call Transcript
On Friday, HLS Therapeutics (TSX:HLS) discussed first-quarter financial results...
05-15 23:31
Merck reports 5-year KEYNOTE-942 data for mRNA-4157 plus Keytruda in melanoma
Merck reports 5-year KEYNOTE-942 data for mRNA-4157 plus Keytruda in melanoma Merck flagged late-stage updates across its oncology portfolio scheduled for presentation at ASCO 2026, led by long-term follow-up from KEYNOTE-942 testing individualized neoantigen therapy intismeran autogene with Keytrud
05-12 18:45
ADMA Biologics Earnings Call: ASCENIV Fuels Profits
ADMA Biologics Inc (($ADMA)) has held its Q1 earnings call. Read on for the mai...
05-08 10:24
ADMA Biologics declines 17% after lowering FY26 outlook, withdrawing long-term guidance
ADMA Biologics (ADMA) declined more than 17% on Thursday after the company lowered its full-year outlook and withdrew its long-term guidance, citing “uncertainty in the competitive landscape”. The sto...
05-08 00:17
BUZZ-Street View: Azure gains keep Microsoft bulls onside despite capex overhang
BUZZ-Street View: Azure gains keep Microsoft bulls onside despite capex overhang ** Microsoft MSFT.O said on Weds that Azure cloud revenue would beat Wall St forecasts and announced $190 bln in capital spending for 2026, exceeding expectations ** Shares down 1.1% premarket AZURE ASCENDS ** Citigroup
04-30 16:24
Why Is Amneal Pharmaceuticals Stock Gaining Today?
Amneal Pharmaceuticals rises premarket after $1.1B Kashiv BioSciences deal to expand biosimilars platform and tap $300B biologics opportunity, while raising FY26 outlook.
04-22 19:15
BRIEF-Our Bond Inc - Enters Amendment No. 2 To Securities Purchase Agreement With Ascent On March 29, 2026 - SEC Filing
BRIEF-Our Bond Inc - Enters Amendment No. 2 To Securities Purchase Agreement With Ascent On March 29, 2026 - SEC Filing March 30 (Reuters) - SEC Filing: OUR BOND INC - ENTERS AMENDMENT NO. 2 TO SECURITIES PURCHASE AGREEMENT WITH ASCENT ON MARCH 29, 2026 - SEC FILING OUR BOND, INC. - 8-K OUR BOND INC
03-30 21:26
ADMA Biologics Rebuts Short Seller Claims, Defends Product Demand
ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today responded to a
03-27 19:08
ADMA Biologics drops amid short report from Culper Research
ADMA Biologics (ADMA) fell 15% amid a short report from Culper Research. Culper Research disclosed that it's short shares of ADMA Biologics (ADMA). ADMA (ADMA) didn't immediately respond to Seeking ...
03-25 02:44
Amarin Highlights 2026 ACC/AHA Dyslipidemia Guideline Emphasizing CV Risk Management In Hypertriglyceridemia
Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, applauded the recommendation that the treatment of CV risk in patients with
03-18 20:33
